Sep 30, 2021 / 12:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the virtual briefing of Synairgen's unaudited half-year financial results for the six months ending June 30, 2021. As a reminder, participants watching the webcast can submit questions at any time during the presentation using the ask a question button. Please note that these questions will be answered after the event.
I will now hand over to Richard Marsden, Chief Executive Officer of Synairgen, to begin the presentation. Please go ahead.
Richard Marsden - Synairgen plc - CEO & Executive Director
Hello. My name is Richard Marsden; I am CEO of Synairgen. And I'm going to give you a full update today on the progress we've made developing SNG001 as a broad-spectrum antiviral directed at COVID-19 patients who are in hospital.
SNG001 is an inhaled formulation delivered by a specific nebulizer. And the formulation contains a protein called interferon beta, which is a key cytokine that has been likened to the conductor of an orchestrator.
It drives many antiviral pathways in cells. And the
Half Year 2021 Synairgen PLC Earnings Call Transcript
Sep 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers